Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) CEO Yuval Cohen bought 1,340 shares of Corbus Pharmaceuticals Holdings stock in a transaction on Tuesday, November 22nd. The shares were purchased at an average cost of $7.64 per share, for a total transaction of $10,237.60. Following the completion of the purchase, the chief executive officer now directly owns 12,830 shares of the company’s stock, valued at $98,021.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) traded down 2.201% on Wednesday, hitting $7.775. 1,015,953 shares of the company were exchanged. Corbus Pharmaceuticals Holdings Inc. has a 52-week low of $1.01 and a 52-week high of $10.78. The firm’s market cap is $345.50 million. The company has a 50-day moving average price of $7.30 and a 200 day moving average price of $4.64.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

A number of research firms have recently issued reports on CRBP. Aegis reissued a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Sunday, August 21st. Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 price target on shares of Corbus Pharmaceuticals Holdings in a research note on Wednesday, October 26th. JMP Securities boosted their price target on shares of Corbus Pharmaceuticals Holdings from $9.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, November 15th. Finally, Noble Financial reissued a “buy” rating and issued a $19.00 price target on shares of Corbus Pharmaceuticals Holdings in a research note on Friday, November 11th.

A number of large investors have recently modified their holdings of CRBP. Milestone Group Inc. acquired a new stake in shares of Corbus Pharmaceuticals Holdings during the third quarter worth approximately $102,000. Bainco International Investors acquired a new stake in shares of Corbus Pharmaceuticals Holdings during the third quarter worth approximately $136,000. Bank of New York Mellon Corp acquired a new stake in shares of Corbus Pharmaceuticals Holdings during the third quarter worth approximately $155,000. Morgan Stanley boosted its stake in shares of Corbus Pharmaceuticals Holdings by 12.4% in the third quarter. Morgan Stanley now owns 29,909 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,300 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Corbus Pharmaceuticals Holdings by 41.0% in the third quarter. Northern Trust Corp now owns 45,436 shares of the biopharmaceutical company’s stock worth $309,000 after buying an additional 13,222 shares during the last quarter. 25.47% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/23/corbus-pharmaceuticals-holdings-inc-crbp-ceo-yuval-cohen-purchases-1340-shares.html.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.